Evidence map›Paper›PMID 36194371›Full record

ReviewCellular and molecular life sciences : CMLS2022

Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action.

Mitra Behroozaghdam, Maryam Dehghani, Amirhossein Zabolian, Davood Kamali, Salar Javanshir, Farzaneh Hasani Sadi, Mehrdad Hashemi, Teimour Tabari, Mohsen Rashidi, Sepideh Mirzaei and 4 more

Open access · greenAbstract readReview
In one paragraph

Review in Cellular and molecular life sciences : CMLS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
6.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 3 countries.

Mitra BehroozaghdamCancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, 1983969411, Iran.
Maryam DehghaniFarhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, 193951495, Iran.
Amirhossein ZabolianDepartment of Orthopedics, School of Medicine, 5th Azar Hospital, Golestan University of Medical Sciences, Golestan, 4913815739, Iran.
Davood KamaliSchool of Medicine, Tehran University of Medical Sciences, Tehran, 141556559, Iran.
Salar JavanshirSchool of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, 193951495, Iran.
Farzaneh Hasani SadiSchool of Medicine, Kerman University of Medical Sciences, Kerman, 7616913555, Iran.
Mehrdad HashemiFarhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, 193951495, Iran.
Teimour TabariDepartment of Clinical Sciences, Faculty of Veterinary Medicine, University of Tehran, Tehran, 1417935840, Iran.
Mohsen RashidiDepartment Pharmacology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, 4815733971, Iran. dr.mohsenrashidi@yahoo.com.
Sepideh MirzaeiDepartment of Biology, Faculty of Science, Islamic Azad University, Science and Research Branch, Tehran, 1477893855, Iran. sepidehmirzaei.smv@gmail.com.
Atefeh ZarepourDepartment of Biomedical Engineering, Faculty of Engineering and Natural Sciences, Istinye University, Istanbul, 34396, Turkey.
Ali ZarrabiDepartment of Biomedical Engineering, Faculty of Engineering and Natural Sciences, Istinye University, Istanbul, 34396, Turkey.
Danielle De GreefCollege of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, FL, 34211, USA.
Anupam BishayeeCollege of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, FL, 34211, USA. abishayee@lecom.edu.ORCID http://orcid.org/0000-0001-9159-960X
Islamic Azad University Medical Branch of Tehran · IRIstinye University · TRLake Erie College of Osteopathic Medicine · USGolestan University · IRIslamic Azad University, Science and Research Branch · IRKerman University of Medical Sciences · IRMazandaran University of Medical Sciences · IRTehran University of Medical Sciences · IRUniversity of Tehran · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer (BC) is one of the most common cancers in females and is responsible for the highest cancer-related deaths following lung cancer. The complex tumor microenvironment and the aggressive behavior, heterogenous nature, high proliferation rate, and ability to resist treatment are the most well-known features of BC. Accordingly, it is critical to find an effective therapeutic agent to overcome these deleterious features of BC. Resveratrol (RES) is a polyphenol and can be found in common foods, such as pistachios, peanuts, bilberries, blueberries, and grapes. It has been used as a therapeutic agent for various diseases, such as diabetes, cardiovascular diseases, inflammation, and cancer. The anticancer mechanisms of RES in regard to breast cancer include the inhibition of cell proliferation, and reduction of cell viability, invasion, and metastasis. In addition, the synergistic effects of RES in combination with other chemotherapeutic agents, such as docetaxel, paclitaxel, cisplatin, and/or doxorubicin may contribute to enhancing the anticancer properties of RES on BC cells. Although, it demonstrates promising therapeutic features, the low water solubility of RES limits its use, suggesting the use of delivery systems to improve its bioavailability. Several types of nano drug delivery systems have therefore been introduced as good candidates for RES delivery. Due to RES's promising potential as a chemopreventive and chemotherapeutic agent for BC, this review aims to explore the anticancer mechanisms of RES using the most up to date research and addresses the effects of using nanomaterials as delivery systems to improve the anticancer properties of RES.

Indexed as

Antineoplastic AgentsBreast NeoplasmsStilbenesApoptosisCell Line, TumorCisplatinDocetaxelDoxorubicinFemaleHumansPaclitaxelPolyphenolsResveratrolTumor MicroenvironmentWaterAntineoplastic AgentsCisplatinDocetaxelDoxorubicinPaclitaxelPolyphenolsResveratrolStilbenesWaterApoptosisBreast cancerDrug resistanceNano-scale deliveryRadiotherapyResveratrol

Identifiers

PMID36194371
PMCPMC11802982
OpenAlexW4301183061

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.